Shots:

• The P-IV VERIFY study involves assessing of Galvus (50mg- bid) + Metformin (1000–2000 mg- qd) vs SOC monothx. approach with metformin initiated in treatment naïve patients (n=2001) in a ratio (1:1)- recently diagnosed with T2DM across 34 countries for 5yrs.
• The P-IV VERIFY study resulted in meeting its 1EPs i.e- 49% reduction in the risk for time to initial treatment failure as defined as HbA1c >=7%- showed a lower frequency of secondary failure with consistent safety & tolerability profile
• Vildagliptin/Metformin dual regimen is the combination of two anti-diabetic agents with complementary mechanism and is the single pill dual therapy of DPP-4 inhibitor with metformin to be approved in Japan & Europe

Click here to­ read full press release/ article | Ref: Novartis | Image: Pharma News